Effectiveness and safety of omalizumab in a patient with chronic urticaria and hepatitis C

Leiva-Salinas, Maria; Francés, Laura Soto; Marín-Cabañas, Irene; Granados, María P.; Silvestre, J.F.

doi:10.1111/jdv.12450

Cited by 13 publications

(9 citation statements)

References 10 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In some patients, chronic urticaria reportedly developed in the prodromal phase of acute hepatitis B or following acute hepatitis A and resolved after hepatitis improvement . In one patient, CSU reportedly appeared upon HCV reactivation …”

Section: Discussionmentioning

confidence: 99%

Comorbidity of viral hepatitis and chronic spontaneous urticaria: A systematic review

Kolkhir

Pereverzina

Olisova

et al. 2018

Allergy

View full text Add to dashboard Cite

Chronic viral infections including those by hepatitis B (CHB) virus and hepatitis C (CHC) virus have been reported to be comorbidities of chronic spontaneous urticaria (CSU). Here, we performed the first comprehensive review of the peer-reviewed literature (PubMed, Web of Science and Google Scholar) on the prevalence of CHB and CHC in patients with CSU and vice versa. The prevalence of CHB and CHC in CSU does not appear to be increased. Less than 5% and 2% of patients with CSU have markers of CHB and CHC, respectively, according to most of the 32 studies reviewed. Urticarial rash including CSU occurs in ≤3% of patients with CHC as reported by most of 20 studies analysed. Very few patients have been assessed for the effects of antiviral hepatitis treatment on their CSU, and two but not all reportedly showed improvement. Hepatitis B/C infections appear unlikely to be linked to CSU. We suggest that routine screening for these infections in patients with CSU is not relevant or cost-effective and should not be performed unless liver function tests are abnormal, risk factors or symptoms of viral hepatitis are present, or urticarial vasculitis is suspected.

show abstract

Section: Discussionmentioning

confidence: 99%

Comorbidity of viral hepatitis and chronic spontaneous urticaria: A systematic review

Kolkhir

Pereverzina

Olisova

et al. 2018

Allergy

View full text Add to dashboard Cite

show abstract

“…8 The beneficial effects of omalizumab in CSU were demonstrated in several multicentre randomized controlled trials (X-CUISITE 21 , MYSTIQUE 22 , ASTERIA I 16 , ASTERIA II 14 and GLACIAL 15 ), and its efficacy and safety has been confirmed by small clinical and real-life studies 18,[23][24][25] and patient case reports. [26][27][28][29] A retrospective, real-life study investigated optimal dosing, efficacy and safety of omalizumab and time to relapse following treatment discontinuation in 51 patients with CU. 18 The study included 20 patients with CSU alone, 21 patients with chronic inducible urticaria (CINDU) and 10 patients with both CSU and CINDU.…”

Section: How the Pathogenesis Of Chronic Urticaria Has Driven New Trementioning

confidence: 99%

Management and treatment of chronic urticaria (CU)

Maurer

Church

Gonçalo

et al. 2015

Acad Dermatol Venereol

View full text Add to dashboard Cite

Developments increasing our understanding of chronic urticaria have resulted in the simplification and improvement of available treatments. Currently, many treatments target mast cell mediators, but we can now disrupt mast cell activation with the anti-IgE antibody omalizumab, which has markedly advanced the treatment landscape for patients with difficultto-treat urticaria. Current guidelines provide a framework for the management and treatment of patients with CU but, as each patient is different, knowledge and experience of specialist dermatologists and allergists are key to effective pharmacotherapy. This article reviews the different therapeutic options for patients with chronic spontaneous urticaria (also called chronic idiopathic urticaria) or chronic inducible urticaria and discusses management of special populations or special circumstances related to CU.

show abstract

“…Furthermore, as a well-established licensed pharmacotherapy for CSU and severe allergic asthma, it has shown to be a welltolerated treatment option with minimal side effects in comparison to some of the alternative (un-licensed) treatment options [52]. Case reports and real-life retrospective observational studies, in summary with a high level of evidence, also indicate that omalizumab works as well in chronic inducible urticarias, some of which are currently being evaluated in clinical trials [21][22][23][24][25][26][46][47][48]. In the algorithm of the international guidelines, this evidence already has led to a strong recommendation to use omalizumab as third-line treatment in all CU subtypes.…”

Section: Resultsmentioning

confidence: 98%

“…Since 2006, there have been a number of case reports with single or small numbers of patients on the use of omalizumab in CU, outside of its licensed indication: for example, cold urticaria with anaphylaxis and persistent asthma in a child [21]; cholinergic urticaria [23]; solar urticaria [24]; severe CU in a child [25]; CU with hepatitis C [26]; symptomatic dermatographism [40]; pressure urticaria [41] as well as CSU, symptomatic dermatographism and pressure urticaria in a pregnant patient [42].…”

Section: Real-life Clinical Practicementioning

confidence: 99%

“…However, beyond these most basic understandings of how omalizumab modulates the IgE-FcRI-mast cell axis, specific mode of action(s) of omalizumab with respect to its beneficial actions in a number of different pathologies is as yet unknown [21][22][23][24][25][26]. This is especially true in urticaria, where the mechanism is not fully understood as omalizumab shows an excellent positive response rate in all CU subtypes, independent of IgE levels and unlike in asthma, a complete response is often observed after as little as 24 h after first injection.…”

Section: How Does Omalizumab Work?mentioning

confidence: 99%

See 1 more Smart Citation

Omalizumab for the treatment of chronic urticaria

Zuberbier

Maurer

2015

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

Urticaria is a common and often debilitating dermatological condition defined by the sudden appearance of wheals, angioedema or both. It is further classified into specific subtypes based on duration and specific triggers. Awareness and understanding of urticaria are important to ensure a correct initial diagnosis and initiate appropriate guideline-based treatment outlining a stepwise approach. However, in chronic urticaria, approximately 50% of patients are refractory to the first step, the use of licensed doses of second-generation H1-antihistamines. If the second step, an increase in the dose of the second-generation H1-antihistamines, is also not successful, in the third step omalizumab (Xolair™, Novartis Pharma AG(©)/Genentech, Inc.(©)), an anti-IgE therapy, is recommended as an add-on. Of all alternative treatments mentioned in the guidelines, omalizumab is currently the only licensed treatment for H1-antihistamine-refractory chronic spontaneous urticaria, has a favorable risk/benefit ratio and was well tolerated in clinical studies.

show abstract

Effectiveness and safety of omalizumab in a patient with chronic urticaria and hepatitis C

Cited by 13 publications

References 10 publications

Comorbidity of viral hepatitis and chronic spontaneous urticaria: A systematic review

Comorbidity of viral hepatitis and chronic spontaneous urticaria: A systematic review

Management and treatment of chronic urticaria (CU)

Omalizumab for the treatment of chronic urticaria

Contact Info

Product

Resources

About